Beranda › Penyakit Payudara › California
Uji klinis Penyakit Payudara di California
6 studi untuk Penyakit Payudara mencari peserta di lokasi di California.
Kota di California
Teks studi resmi (Bahasa Inggris)
ATUSA Ultrasound Diagnostic Imaging for Breast Lesions Evaluation (AUDIBLE) - iSono Health
- UC Davis, Sacramento
Menerima pesertaStudi observasional
Usia 18 hingga 94 · Wanita · Diperbarui 17 Sep 2026 · NCT07505797A Study of Breast Cancer Risk Factors and Outcomes of People in Florida
- University of California, Los Angeles (Specimen Analysis only), Los Angeles
Menerima pesertaStudi observasionalSukarelawan sehat diterima
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 16 Sep 2026 · NCT06780176Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
- Providence Medical Foundation, Fullerton
- California Research Institute, Los Angeles
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 9 Sep 2026 · NCT05386108A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer
- Research Site, Duarte
- Research Site, Palo Alto
Menerima pesertaFase 3
Usia 18 hingga 130 · Semua jenis kelamin · Diperbarui 8 Sep 2026 · NCT07647328First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
- Ellison Clinic at Saint John's, Los Angeles
- UCSF Medical Center at Mission Bay, San Francisco
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 7 Jul 2026 · NCT05768139Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
- Hoag Memorial Hospital Presbyterian, Newport Beach
- UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 23 Jun 2026 · NCT06993844Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.